Healthcare Providers and Services
Company Overview of Joslin Diabetes Center, Inc.
Joslin Diabetes Center, Inc. operates as a diabetes research center in the United States. It specializes in diabetes treatment and research; and develops and disseminates patient therapies and scientific discoveries worldwide. The company was founded in 1898 and is headquartered in Boston, Massachusetts.
One Joslin Place
Boston, MA 02215
Founded in 1898
Key Executives for Joslin Diabetes Center, Inc.
Chief Executive Officer and President
Chief Financial Officer, Chief Operating Officer and Treasurer
Chief Scientific Officer, Senior Vice President and Trustee
Senior Vice President of Medical Affairs
Compensation as of Fiscal Year 2016.
Joslin Diabetes Center, Inc. Key Developments
Joslin Diabetes Center Announces Extended Collaboration with Sanofi for the Development of Novel Treatments for Diabetes Complications
Jun 9 16
Joslin Diabetes Center announced a newly signed collaboration with Sanofi which extends their ongoing collaboration in exploring novel targets for treatment of diabetes. The parties will direct joint efforts on research and development of new therapeutic options for the treatment of diabetic nephropathy, and explore implications of diabetes on cardiovascular disease.
Joslin Diabetes Center Appoints John A Perry as Chief Development Officer
Feb 2 16
Joslin Diabetes Center has appointed John A. Perry, CFRE, a skilled fundraising professional with extensive experience in healthcare philanthropy, as Chief Development Officer effective February 1, 2016. Mr. Perry's three decades of fundraising experience includes 15 years within the medical and healthcare sectors. His previous appointment was at Brown University's Warren Alpert Medical School, where he was Senior Associate Dean for Medical Advancement, serving as the Chief Advancement Officer in charge of philanthropy, stewardship, and alumni and parent relations for the medical school.
Joslin Diabetes Center Appoints Peter Amenta as New President and CEO, Effective Oct. 5, 2015 in Replace of John Brooks
Sep 15 15
Joslin Diabetes Center announced a new president and CEO, a week after seeking and getting the resignation its previous CEO of five years. Dr. Peter Amenta has been appointed to the position, effective Oct. 5, 2015. The move effectively comes from within; in addition to serving as dean of the Rutgers Robert Wood Johnson Medical School for eight years, Amenta sat on the Joslin board of trustees for five years. Amenta left the board of trustees earlier 2015 to take on a consultant role and advisor. The move comes exactly a week after John Brooks III resigned from the position. Brooks also had been promoted to the CEO role in 2011 from a member of the organization's board of directors. He reportedly was asked to resign last week, a move that came unexpectedly. Amenta has also worked at University Hospital of New Jersey and was former CEO of the Robert Wood Johnson Medical Group.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create
or control the content. For inquiries, please contact Capital IQ directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries